Company Logo
Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) — “Lancing Device Market Size, Share & Trends Analysis Report 2026-2033” has been added to ResearchAndMarkets.com’s offering.
The global lancing device market was valued at USD 3.5 billion in 2025 and is projected to increase from USD 3.7 billion in 2026 to USD 6.6 billion by 2033, expanding at a CAGR of 8.5% from 2026 to 2033. North America led the global market with a revenue share of 42.5% in 2025, supported by widespread diabetes monitoring, established healthcare infrastructure, and strong adoption of self-monitoring blood glucose (SMBG) products.
Market growth is being driven by the rising prevalence of diabetes, expansion of home-based diabetes management, and sustained demand for convenient capillary blood sampling. Increased use of low-pain, adjustable-depth, ergonomic, and safety-engineered lancing devices across home-care and clinical environments is also contributing to industry expansion. Product innovation focused on comfort, safety, accuracy, and ease of use is expected to support continued adoption among patients and healthcare professionals.
The global diabetes burden represents a significant long-term growth driver. According to the International Diabetes Federation (IDF) Diabetes Atlas, 11th Edition (2025), the number of adults living with diabetes is forecast to rise from 588.7 million in 2024 to 852.5 million by 2050. This increase is expected to create sustained demand for blood glucose monitoring products and related capillary blood sampling solutions.
Emerging markets are anticipated to generate substantial opportunities for lancing device manufacturers and distributors. Africa is projected to record a 142% increase in adults living with diabetes, supported by expanding diabetes-care infrastructure and improving access to monitoring technologies. MENA and South-East Asia are expected to experience increases of 92% and 73%, respectively, strengthening demand for affordable, reliable, and easy-to-use products. The Western Pacific region will remain an important market due to its large diabetic population and increasing focus on disease management.
Market Segmentation Covered in the Report
The report provides global, regional, and country-level revenue analysis from 2021 to 2033, alongside industry trends, growth opportunities, competitive developments, and market forecasts. The lancing device market is segmented by product, end-use, application, distribution channel, and region.
Product: Reusable Adjustable-Depth Lancing Pens, Reusable Fixed-Depth Lancing Pens, and Single-Use Safety Lancing Devices
End-use: Home-care use, Hospital, Clinical / Diagnostic laboratories, Physician office, and Long-term care facilities
Application: Blood glucose monitoring, Cholesterol / Lipid Panel Testing, Hemoglobin / Anemia Screening, Coagulation Testing, Cardiac Enzyme / Point-of-Care Diagnostic Testing, and Neonatal Screening
Distribution channel: Retail Channels, Retail Pharmacy/OTC, E-commerce/DTC, Institutional Channels, Hospital, and Diagnostic chains & clinical labs procurement
Regional Market Coverage
The geographic analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Country-level coverage includes the U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, Denmark, Sweden, Norway, Japan, China, India, Thailand, Australia, South Korea, Brazil, Argentina, South Africa, Saudi Arabia, UAE, and Kuwait.
Strategic Value of the Report
Detailed market intelligence supporting informed business and investment decisions
Revenue forecasts across major products, applications, end-use settings, distribution channels, and regions
Analysis of market growth drivers, emerging trends, and commercial opportunities
Competitive landscape insights, including market presence and strategic positioning
Actionable recommendations for identifying revenue opportunities and planning market expansion
Assessment of product innovation and evolving diabetes monitoring requirements
The report enables manufacturers, healthcare suppliers, distributors, investors, and other industry participants to evaluate the lancing device market, identify high-growth segments, and develop strategies aligned with changing patient needs. Rising diabetes prevalence, increasing patient participation in disease management, broader healthcare access, and continued innovation in blood sampling technologies are expected to sustain global market growth through 2033.
Companies Featured
Roche Diabetes Care (Roche Holding AG)
LifeScan Enterprises LLC. (Platinum Equity)
Ascensia Diabetes Care Holdings AG (PHC Holdings)
Trividia Health, Inc. (Sinocare Group)
Owen Mumford (Embecta Corp.)
BD
Bionime Corporation
Abbott Laboratories
B. Braun SE
Greiner Bio-One International GmbH
Terumo Corporation
SARSTEDT AG & Co. KG
HTL Strefa
I-SENS, Inc.
LetsGetChecked
For more information about this report visit https://www.researchandmarkets.com/r/kujrd1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
